Bending the cost curve in cancer care.

The current growth in the cost of cancer care is unsustainable. The authors provide data-driven proposals that have the potential to save money without compromising patient care.

[1]  道子 相原,et al.  薬疹up to date , 2011 .

[2]  Thomas J. Smith,et al.  A pilot trial of decision aids to give truthful prognostic and treatment information to chemotherapy patients with advanced cancer. , 2011, The journal of supportive oncology.

[3]  Thomas J. Smith,et al.  American society of clinical oncology statement: toward individualized care for patients with advanced cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Eric J Feuer,et al.  Projections of the cost of cancer care in the United States: 2010-2020. , 2011, Journal of the National Cancer Institute.

[5]  Corneel Coens,et al.  Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial , 2010, The Lancet.

[6]  P. Bach,et al.  How Medicare could use comparative effectiveness research in deciding on new coverage and reimbursement. , 2010, Health affairs.

[7]  Alona Muzikansky,et al.  Early palliative care for patients with metastatic non-small-cell lung cancer. , 2010, The New England journal of medicine.

[8]  C. Earle,et al.  How Medicare's payment cuts for cancer chemotherapy drugs changed patterns of treatment. , 2010, Health affairs.

[9]  Thomas J. Smith,et al.  Giving honest information to patients with advanced cancer maintains hope. , 2010, Oncology.

[10]  E. Elkin,et al.  Cancer's next frontier: addressing high and increasing costs. , 2010, JAMA.

[11]  Thomas J. Smith,et al.  Comment on pegylated liposomal Doxorubicin plus docetaxel in metastatic breast cancer. , 2010, Journal of Clinical Oncology.

[12]  Thomas J. Smith,et al.  Concrete options and ideas for increasing value in oncology care: the view from one trench. , 2010, The oncologist.

[13]  K. Kahn,et al.  Physician factors associated with discussions about end‐of‐life care , 2010, Cancer.

[14]  H. Brody.  Medicine's ethical responsibility for health care reform--the Top Five list. , 2010, The New England journal of medicine.

[15]  Thomas J. Smith,et al.  Paradoxes in advance care planning: the complex relationship of oncology patients, their physicians, and advance medical directives. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Thomas J. Smith,et al.  American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  P. Bach.  Limits on Medicare's ability to control rising spending on cancer drugs. , 2009, The New England journal of medicine.

[18]  Jing Jing Li,et al.  Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada. , 2009, JAMA.

[19]  E. Winer,et al.  International Guidelines for Management of Metastatic Breast Cancer: Combination vs Sequential Single-Agent Chemotherapy , 2009, Journal of the National Cancer Institute.

[20]  P. Ginsburg,et al.  Is health spending excessive? If so, what can we do about it? , 2009, Health affairs.

[21]  T. Brennan,et al.  A comprehensive case management program to improve palliative care. , 2009, Journal of palliative medicine.

[22]  David Hanauer,et al.  Implementation of the Quality Oncology Practice Initiative at a university comprehensive cancer center. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  C. Grady,et al.  How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. , 2009, Journal of the National Cancer Institute.

[24]  K. Kahn,et al.  Discussions with physicians about hospice among patients with metastatic lung cancer. , 2009, Archives of internal medicine.

[25]  Thomas J. Smith,et al.  Efficacy does not necessarily translate to cost effectiveness: a case study in the challenges associated with 21st-century cancer drug pricing. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Karen R. Sepucha,et al.  Is There a Role for Decision Aids in Advanced Breast Cancer? , 2009, Medical decision making : an international journal of the Society for Medical Decision Making.

[27]  C. Earle,et al.  Health care costs in the last week of life: associations with end-of-life conversations. , 2009, Archives of internal medicine.

[28]  P. Maciejewski,et al.  Associations between end-of-life discussions, patient mental health, medical care near death, and caregiver bereavement adjustment. , 2008, JAMA.

[29]  S. Block,et al.  A qualitative study of oncologists' approaches to end-of-life care. , 2008, Journal of Palliative Medicine.

[30]  Thomas J. Smith,et al.  The role of chemotherapy at the end of life: "when is enough, enough?". , 2008, JAMA.

[31]  Angela Mariotto,et al.  Cost of care for elderly cancer patients in the United States. , 2008, Journal of the National Cancer Institute.

[32]  Michael N Neuss,et al.  Improvement in oncology practice performance through voluntary participation in the Quality Oncology Practice Initiative. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  R. D. Della Penna,et al.  Impact of an inpatient palliative care team: a randomized control trial. , 2008, Journal of palliative medicine.

[34]  Kimberly S. Chiew,et al.  Development and evaluation of a decision aid for patients considering first‐line chemotherapy for metastatic breast cancer , 2008, Health expectations : an international journal of public participation in health care and health policy.

[35]  E. Adang,et al.  Modeling the cost effectiveness of secondary febrile neutropenia prophylaxis during standard-dose chemotherapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  G. Lyman,et al.  Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  S. Enguídanos,et al.  Increased Satisfaction with Care and Lower Costs: Results of a Randomized Trial of In‐Home Palliative Care , 2007, Journal of the American Geriatrics Society.

[38]  G. Hortobagyi.  A shortage of oncologists? The American Society of Clinical Oncology workforce study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  K. Iwasaki,et al.  Comparing hospice and nonhospice patient survival among patients who die within a three-year window. , 2007, Journal of pain and symptom management.

[40]  T. Bodenheimer,et al.  The Primary CareSpecialty Income Gap: Why It Matters , 2007, Annals of Internal Medicine.

[41]  Daniel F Hayes,et al.  ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  Thomas J. Smith,et al.  American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  Michael J. Byrne,et al.  People's perceptions of cancer survivability: implications for oncologists. , 2006, The Lancet. Oncology.

[44]  Thomas J. Smith,et al.  Why do patients choose chemotherapy near the end of life? A review of the perspective of those facing death from cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  Thomas J. Smith,et al.  2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  C. Earle,et al.  Does reimbursement influence chemotherapy treatment for cancer patients? , 2006, Health affairs.

[47]  Thomas J. Smith.  The American Society of Clinical Oncology Recommended Breast Cancer Surveillance Guidelines can be done in a routine office visit. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  K. Fitch,et al.  Medicare cost in matched hospice and non-hospice cohorts. , 2004, Journal of pain and symptom management.

[49]  C. Loprinzi,et al.  Doc, shouldn't we be getting some tests? , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  Russell S. Kirby,et al.  The Dartmouth Atlas of Health Care , 1998 .

[51]  Thomas J. Smith,et al.  Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. American Society of Clinical Oncology. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  T. Smith,et al.  Ethical considerations in oncology: balancing the interests of patients, oncologists, and society. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  N. Urban,et al.  A minimalist policy for breast cancer surveillance. , 1991, JAMA.

[54]  C. Mitton,et al.  International Comparison of Comparative Effectiveness Research in Five Jurisdictions , 2012, PharmacoEconomics.

[55]  Lonny Reisman,et al.  Cost effectiveness of evidence-based treatment guidelines for the treatment of non-small-cell lung cancer in the community setting. , 2010, Journal of oncology practice.

[56]  B. Ljung,et al.  Breast cancer. Clinical practice guidelines in oncology. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

[57]  D. Ghersi,et al.  Single agent versus combination chemotherapy for metastatic breast cancer. , 2005, The Cochrane database of systematic reviews.

[58]  G. Schwarzer,et al.  Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. , 2004, The Cochrane database of systematic reviews.